Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Telmisartan
Drug ID BADD_D02147
Description Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Indications and Usage Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
Marketing Status approved; investigational
ATC Code C09CA07
DrugBank ID DB00966
KEGG ID D00627
MeSH ID D000077333
PubChem ID 65999
TTD Drug ID D0N6RF
NDC Product Code 72606-506; 10695-139; 65841-805; 68462-199; 68462-200; 72606-507; 55111-095; 62135-536; 62135-537; 62332-089; 65162-293; 71209-049; 52286-0024; 53104-7624; 65404-007; 42291-792; 42571-226; 62135-535; 62332-087; 0597-0041; 72241-017; 65841-804; 65862-868; 68071-2591; 72241-015; 72241-016; 65372-1146; 42291-790; 46708-608; 53002-1794; 71335-1428; 71335-2173; 12666-0010; 50370-0015; 64220-124; 65862-727; 68554-0049; 42571-227; 43547-284; 43547-285; 53746-291; 63629-5682; 0378-2920; 67877-482; 68382-472; 68382-473; 70518-3556; 0597-0039; 65404-006; 66039-895; 71052-679; 45865-836; 53746-292; 65841-806; 65862-867; 68071-5178; 71335-1723; 57451-1206; 46708-610; 67877-483; 68788-8440; 68788-8441; 70518-3300; 0597-0040; 62512-0040; 64552-4026; 65015-845; 42291-791; 43547-283; 53746-293; 62332-088; 0378-2921; 65862-869; 67877-484; 68462-201; 70518-2572; 71209-050; 71209-051; 72606-508; 52562-009; 72761-021; 42571-228; 46708-609; 50090-5490; 63187-951; 0378-2922; 65162-291; 65162-292; 68382-471; 71335-2191; 62331-032; 64220-171
UNII U5SYW473RQ
Synonyms Telmisartan | 4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid | Pritor | BIBR 277 | BIBR-277 | Micardis
Chemical Information
Molecular Formula C33H30N4O2
CAS Registry Number 144701-48-4
SMILES CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thalamus haemorrhage24.07.04.033; 17.08.01.0620.000260%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000260%Not Available
Hepatic cytolysis09.01.07.0360.000781%Not Available
Hypertensive urgency24.08.01.005--Not Available
Injection site hypoaesthesia17.02.06.051; 12.07.03.060; 08.02.03.060--Not Available
Nasal flaring22.12.02.008--Not Available
Post micturition dribble20.02.02.0280.000521%Not Available
Renal tubular dysfunction20.05.03.0280.000521%Not Available
Sprue-like enteropathy14.02.01.011; 07.17.01.0140.001171%Not Available
Therapeutic product effect incomplete08.06.01.0520.000390%Not Available
Therapy non-responder08.06.01.0630.000521%Not Available
Throat clearing22.12.03.0280.000260%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 14th Page    First    Pre   14    Total 14 Pages